Medtronic plc: Q2 2026 (Fiscal Year) Summary
Business Context and Reporting Period
This summary covers Medtronic plc's Form 10-Q for the quarterly period ended October 24, 2025 (Fiscal Q2 2026). Medtronic is a global healthcare technology company operating through four reportable segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company is currently executing a plan to separate its Diabetes business into an independent, publicly traded company, expected to be completed within 18 months of the May 2025 announcement.
Key Financial Metrics
| Metric (in millions) | Q2 2026 (3 Months) | Q2 2025 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|---|
| Net Sales | $8,961 | $8,403 | $17,539 | $16,318 |
| Operating Profit | $1,686 | $1,595 | $3,130 | $2,873 |
| Net Income (Attributable to Medtronic) | $1,374 | $1,270 | $2,414 | $2,312 |
| Diluted EPS | $1.07 | $0.99 | $1.87 | $1.79 |
| Operating Cash Flow (YTD) | $2,013 (vs. $1,944 prior YTD) | |||
| Free Cash Flow (YTD) | $1,041 (vs. $1,020 prior YTD) | |||
| Total Debt | $29.1 billion (Oct 24, 2025) | |||
| Cash & Investments | $8.3 billion (Oct 24, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% year-over-year (Q2) and 8% year-over-year (YTD). Growth was driven by strong performance in Cardiac Ablation Solutions, TAVR, Neuromodulation, and Diabetes, alongside favorable foreign currency impacts.
- Profitability: Operating profit margin improved to 18.8% in Q2 2026 from 19.0% in Q2 2025. Net income increased 8% in Q2 and 4% YTD.
- Tax Rate: The effective tax rate decreased to 13.5% in Q2 2026 (from 18.0% prior year) and 16.2% YTD (from 17.7% prior year), primarily due to a tax benefit from a change in estimate on accrued interest on uncertain tax positions.
- Italian Payback Adjustment: A $39 million favorable adjustment to net sales was recorded YTD 2026 due to a legislative decree reducing amounts due for prior years, contrasting with a $90 million negative adjustment in the prior year.
- Minority Investment Loss: A $90 million unrealized loss was recognized on the Mozarc Medical investment (50% stake in renal care business) during the six months ended October 24, 2025.
Guidance, Outlook, and Risks
- Tariff Impact: Management estimates a pre-tax net tariff impact of $185 million for fiscal year 2026, with the majority expected in the second half, driven by new U.S., China, and other jurisdiction tariffs.
- Diabetes Separation: The company continues to prepare for the separation of the Diabetes Operating Unit, which is expected to incur exit-of-business-related charges.
- Legal Proceedings:
- Colibri Litigation: The U.S. Court of Appeals for the Federal Circuit ruled in Medtronic's favor in July 2025, reversing a $106 million jury verdict regarding patent infringement.
- Hernia Mesh: Approximately 10,000 individual plaintiffs are involved in pending lawsuits; no expense has been recorded as loss is not currently probable or estimable.
- Applied Medical Antitrust: Trial is set to begin in January 2026 regarding alleged anticompetitive conduct in advanced bipolar devices.
- Capital Allocation: The company repurchased 3.3 million shares in Q2 2026 at an average price of $93.54. Approximately $1.7 billion remains under the $5.0 billion share repurchase authorization.
Investor Verification Checklist
- Tariff Exposure: Verify the specific product lines and geographies most exposed to the estimated $185 million tariff impact in H2 2026.
- Diabetes Spin-off Timeline: Monitor progress on the 18-month separation timeline and associated one-time costs.
- Italian Payback Resolution: Confirm the finality of the legislative decree and potential for future adjustments regarding years 2019 and beyond.
- Mozarc Medical Valuation: Assess the drivers of the $90 million fair value loss on the renal care joint venture and its impact on future earnings.
- Legal Accruals: Review the $0.2 billion accrued litigation balance and the potential for material adverse impact from pending antitrust and product liability cases.